Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787.

about

Clinical Evaluation of Tavocept to Decrease Diuresis Time and Volume in Dogs with Bladder Cancer Receiving Cisplatin.Mutation L1196M-induced conformational changes and the drug resistant mechanism of anaplastic lymphoma kinase studied by free energy perturbation and umbrella sampling.

P2860

Q48109905-AECAFD78-F2F4-4DE2-B769-E79AA01BE92E Q50130090-2EDCC46A-D488-4448-A81A-5D69BAF0BF3A

P2860

Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787.

Item

http://www.wikidata.org/entity/Q43142869

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Novel covalent modification of ...... on of ALK activity by BNP7787.

@en

Novel covalent modification of human anaplastic lymphoma kinase

@nl

type

Item

label

Novel covalent modification of ...... on of ALK activity by BNP7787.

@en

Novel covalent modification of human anaplastic lymphoma kinase

@nl

prefLabel

Novel covalent modification of ...... on of ALK activity by BNP7787.

@en

Novel covalent modification of human anaplastic lymphoma kinase

@nl

P1476

Novel covalent modification of ...... on of ALK activity by BNP7787.

@en

P2093

Aulma R Parker

http://www.w3.org/2001/XMLSchema#string

Barbara Chie-Leon

http://www.w3.org/2001/XMLSchema#string

Cheyenne Logan

http://www.w3.org/2001/XMLSchema#string

Frederick H Hausheer

http://www.w3.org/2001/XMLSchema#string

Harry Kochat

http://www.w3.org/2001/XMLSchema#string

John Badger

http://www.w3.org/2001/XMLSchema#string

Min Zhao

http://www.w3.org/2001/XMLSchema#string

Pavankumar N Petluru

http://www.w3.org/2001/XMLSchema#string

Philippe Y Ayala

http://www.w3.org/2001/XMLSchema#string

Vandana Sridhar

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Anaplastic lymphoma kinase: signalling in development and disease

Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

Refinement of macromolecular structures by the maximum-likelihood method

Heterogeneity in cancer: cancer stem cells versus clonal evolution

Identification of novel peptide substrates for protein farnesyltransferase reveals two substrate classes with distinct sequence selectivities.

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

Mechanisms of ATPases--a multi-disciplinary approach.

Structural analysis of cysteine S-nitrosylation: a modified acid-based motif and the emerging role of trans-nitrosylation.

P304

375-383

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S73690

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25678804

http://www.w3.org/2001/XMLSchema#string

P921

crizotinib

P932

4324543

http://www.w3.org/2001/XMLSchema#string

Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787.

about

P2860

P2860

Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P921

P932